Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.77 |
| ▸ | BLM | P54132 | 3/20 | 0.75 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14507225 | 0.91 | CHRM2 (0.80) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Methylatropine SCHEMBL824874 | 0.87 | CHRM2 (1.00) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Methylatropine SCHEMBL34463463 | 0.87 | CHRM2 (1.00) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| SCHEMBL15095412 | 0.86 | CHRM2 (0.56) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Methylatropine SCHEMBL29389879 | 0.86 | PABPC1 (1.00) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Methylatropine SCHEMBL1321572 | 0.86 | BLM (1.00) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Methylatropine SCHEMBL30647266 | 0.86 | BLM (1.00) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Bromide SCHEMBL29840597 | 0.85 | BLM (0.77) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Atropine Oxide SCHEMBL98985 | 0.85 | CYP2C19 (1.00) | CHRM2BLMPABPC1CYP2C19CHRM1 | |
| Atropine Oxide SCHEMBL29369999 | 0.85 | CYP2C19 (1.00) | CHRM2BLMPABPC1CYP2C19CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266113-A1 | NEBULIZABLE COMPOSITIONS OF QUATERNARY AMMONIUM MUSCARINIC RECEPTOR ANTAGONISTS | DEY LP | 2017-09-21 | — | — | US | disclosed |
| US-20130019861-A1 | NEBULIZABLE COMPOSITIONS OF QUATERNARY AMMONIUM MUSCARINIC RECEPTOR ANTAGONISTS | CHAUDRY IMTIAZ A (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266113-A1 | NEBULIZABLE COMPOSITIONS OF QUATERNARY AMMONIUM MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885BLM 926/4885PABPC1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.